pharma consulting companies

  Description BLINCYTO (blinatumomab) is a CD19-directed bispecific CD3 T cell adaptor that can bind to CD19 (expressed on cells of B lineage origin) and CD3 (expressed on T cells). BLINCYTO is produced in Chinese hamster ovary cells. It is composed of 504 amino acids and has a molecular weight of approximately 54 kilodaltons. Each package of BLINCYTO contains 1 vial of BLINCYTO and 1 vial of IV solution stabilizer. BLINCYTO is provided in a single-dose vial as a sterile, preservative-free white to off-white lyophilized powder for intravenous administration. Each BLINCYTO single-dose vial contains 35 mcg of blinatumomab, citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), trehalose dihydrate (95.5 mg) and hydrogen Sodium oxide adjusts the pH to 7.0. After reconstitution with 3 mL of preservative-free sterile water for injection (USP), the resulting concentration is 12.5 mcg/mL blinatumomab. The IV solution stabilizer is provided in a single...

 Drug Name Atriance 5 mg/ml infusion solution 2. Qualitative and quantitative composition Each milliliter of solution contains 5 mg of Nelarabine. Each vial contains 250 mg of Nelarabine. Excipients with known effects Each milliliter of solution contains 1.770 mg (77 micromoles) of sodium. For a complete list of excipients, see section 6.1. 3. Drug form Infusion solution. Clear colorless solution. 4. Clinical details 4.1 Treatment indications Nelarabine is suitable for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not responded or relapsed after treatment with at least two chemotherapy regimens. Because the number of patients in these conditions is small, the information supporting these indications is based on limited data. 4.2 Modes and methods of administration Nelarabine can only be administered under the guidance of a doctor who has experience in the use of cytotoxic agents. Ontology The complete b...

  What is Arzerra? how to use? Arzerra (ofatumumab) injection is a monoclonal antibody used to treat chronic lymphocytic leukemia. Arzerra is usually given after other drugs have been tried but the symptoms have not been successfully treated. What are the side effects of Arzerra? Common side effects of Arzerra include: nausea, Vomiting diarrhea, tired Swelling of hands/ankles/feet, Difficulty sleeping, Skin rash, or Cold symptoms such as stuffy nose, sneezing and sore throat. Arzerra reduces bone marrow function, which may result in a decrease in the number of blood cells, such as red blood cells, white blood cells and platelets. This side effect of Arzerra can cause anemia, reduce the body's ability to fight infection or cause easy bruising or bleeding. Tell the doctor if you have the following symptoms: Easy bruising/bleeding, Pale skin, Unusual tiredness, or Signs of infection (eg fever, chills, cough, persistent sore throat). caveat Activation of hepatitis B virus and progressi...

  What is Adcetris and how to use it? Adcetris is a prescription medicine used to treat symptoms. Adcetris can be used alone or together with other drugs. Adcetris belongs to a class of drugs, called anti-tumor drugs, anti-microtubules; anti-Nectin-4 monoclonal antibodies; anti-tumor drugs, anti-CD30 monoclonal antibodies. It is not clear whether Adcetris is safe and effective in children. What are the possible side effects of Adcetris? Adcetris can cause serious side effects, including: measles, Difficulty breathing, Swelling of your face, lips, tongue or throat, fever, sore throat, Burn in your eyes Skin pain The red or purple rash spreads and causes blistering and peeling, dizziness, nausea, Chills Itching, Difficulties in speech, thought, vision or muscle movement, numbness, weakness, Burning pain Numbness Loss of sensation in the arms or legs, Sudden chest pain or pressure, respite dry cough, Shortness of breath, Pain or burning when urinating, thirst, Increased urination, Dry...

  Formulations and advantages pill 15 mg 45 mg Chronic myeloid leukemia Suitable for patients in the chronic phase (CP) of chronic myeloid leukemia (CML) who are resistant or intolerant to at least 2 previous kinase inhibitors It is also suitable for accelerated phase (AP) or explosion phase (BP) CML without indication of other kinase inhibitors, and T315I positive CML (CP, AP, BP) CP-CML Initial 45 mg PO qDay When reaching ≤1% BCR-ABL1IS, reduce q to 15 mg PO daily Patients who fail to respond will re-raise the dose to the previously tolerated 30 mg or 45 mg PO qDay dose Continue until the dose is raised again, the reaction disappears or unacceptable toxicity occurs AP-CML or BP-CML The optimal dose has not been determined 45 mg PO qday AP CML Consider reducing the dose of AP CML in patients who have already achieved a major cytogenetic response Continue treatment until loss of response or unacceptable toxicity If there is no response after 3 months, please consider discontinuing ...

  Description SYNRIBO contains the active ingredient omexetine mesylate succinate, a type of ceftazidoxime. It is a protein synthesis inhibitor. Omascitabine syringate is prepared through a semi-synthetic process of ceftazidine, which is an extract of the leaves of the genus Ceftazid. The chemical name of omestatin mesylate succinate is ceftacine, 4-methyl butyrate (2R)-hydroxy-2-(4-hydroxy-4-methylpentyl). Oxcarbetine mesylate succinate has the following chemical structure: SYNRIBO® (Omexitine mesylate succinate) structure diagram The molecular formula is C29H39NO9 and the molecular weight is 545.6 g/mol. SYNRIBO for injection is a single-use sterile, preservative-free, white to off-white freeze-dried powder. Each vial contains 3.5 mg omecetine mesylate succinate and mannitol. SYNRIBO is intended to be reconstituted with 1.0 mL of 0.9% Sodium Chloride Injection (USP) for subcutaneous administration. The pH of the reconstituted solution is between 5.5 and 7.0. Indications and dosag...

  Indications Instruct VENCLEXTA: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Combine with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML): 75 years or older, or Patients with comorbidities cannot use intensive induction chemotherapy. Important safety information Contraindications In patients with CLL/SLL, simultaneous use of VENCLEXTA with strong CYP3A inhibitors is contraindicated because it may increase the risk of tumor lysis syndrome (TLS). Tumor lysis syndrome Patients treated with VENCLEXTA developed tumor lysis syndromes, including fatal events and renal failure requiring dialysis. VENCLEXTA can cause rapid tumor reduction, so in all CLL/SLL patients, there is a risk of TLS during the start and the start phase, and during the restart period after the dose is interrupted. Changes in blood chemistry consistent with TLS need to be dealt wi...

  USE The drug is used to treat certain types of cancer (such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin’s lymphoma, small lymphocytic lymphoma-SLL). Edarassib belongs to a class of drugs called kinase inhibitors. It works by slowing down or stopping the growth of cancer cells. How to use Zydelig See also the warning section. Please read the "Medication Guide" provided by your pharmacist before starting to take Atulixib and every time you supplement it. If you have any questions, please consult your doctor or pharmacist. Follow your doctor's instructions to take this medication by mouth, with or without food, usually twice a day. Swallow the entire tablet. Do not chew or crush the tablets. The dosage depends on your medical condition and response to treatment. Do not increase the dose, and do not use this medication more frequently or longer than prescribed. Your condition will not get better soon, and the risk of side effects will increase. Becaus...

 What is IDHIFA? how to use? IDHIFA is a prescription drug used to treat patients with acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations that have recovered or did not improve after previous treatment. It is not known whether IDHIFA is safe and effective in children. What are the possible side effects of IDHIFA? IDHIFA can cause serious side effects, including: See "What is the most important information I should know about IDHIFA?" The most common side effects of IDHIFA include: nausea Vomiting diarrhea jaundice Decreased appetite Tell your healthcare provider if there is any change in the color of your skin or whites of the eyes. Your healthcare provider will monitor your side effects during treatment, and if you experience certain side effects, they may tell you to stop taking IDHIFA. These are not all possible side effects of IDHIFA. description IDHIFA (Enanib) is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib is a met...

  What is Carbaglu? how to use? Carbaglu (carglumic acid) is an artificial form of liver enzyme used to treat hyperammonemia, which is a urea cycle disorder caused by a lack of certain liver enzymes. Carbaglu is usually used with other drugs to treat this lifelong disease. What are the side effects of Carbaglu? Common side effects of Carbaglu include: Vomiting diarrhea, stomachache, headache, Stuffy nose, sore throat, Ear infections Changes in taste, fever, infection, Flu symptoms lose weight, Lethargy, and rash description CARBAGLU tablets for oral suspension contain 200 mg of pyrophosphate. Active carbamic acid is the activator of carbamoyl phosphate synthase 1 (CPS 1), soluble in boiling water, slightly soluble in cold water, and almost insoluble in organic solvents. The chemical pyroic acid is N-carbamoyl-L-glutamic acid or (190) (2S)-2-(carbamoylamino)glutaric acid with a molecular weight of 190.16. The structural formula is: CARBAGLU® (pyrophosphoric acid)-structure diagram M...

  What is elaplase? Elaplase (idursulfase) is an intravenous infusion used to treat certain symptoms of genetic diseases, known as Hunter’s syndrome, also known as mucopolysaccharidosis (MYOO-koe-pol-ee- SAK-a-rye-DOE-sis). Isosulfite contains a natural enzyme that is lacking due to genetic diseases. Elaplase helps to replace this missing enzyme. Hunter syndrome is a metabolic disorder in which the body lacks the enzymes needed to break down certain sugars and proteins. These substances can accumulate in the body, causing organ enlargement, abnormal bone structure, changes in facial features, breathing problems, heart problems, decreased vision, and changes in mental or physical abilities. Elaplase can improve the walking ability of people in this situation. However, this drug cannot cure Hunter syndrome. warning Elaplase can improve the walking ability of patients with Hunter syndrome. However, elaplase cannot cure this condition. Some side effects may occur during or up to 24 hou...

 What is ZAVESCA? how to use? ZAVESCA is a prescription drug used only to treat adults with mild to moderate type 1 Gaucher disease. ZAVESCA is only for people who cannot receive enzyme replacement therapy. It is not clear whether ZAVESCA is safe and effective in children under 18 years of age. What are the possible side effects of ZAVESCA? ZAVESCA may cause serious side effects, including: Numbness, tingling, pain, or burning in the hands or feet (peripheral neuropathy). If you feel numbness, tingling, pain or burning in your hands and feet, call your healthcare provider immediately. Before you start ZAVESCA and during ZAVESCA treatment, your healthcare provider may test your nerves (neurological examination). New or worsening hand tremor (shaking). Tremors are common in ZAVESCA and may begin within the first month of starting treatment. Sometimes, if treatment is continued, the tremor may disappear within 1 to 3 months. If you experience new or worsening hand tremors, your health...

  What is CERDELGA? how to use? CERDELGA is a prescription drug used for the long-term treatment of adult Gaucher disease type 1 (GD1). Some people with Gaucher disease type 1 do not use CERDELGA. Your doctor will check to make sure that CERDELGA is right for you. It is not known whether CERDELGA is safe and effective in children. What are the possible side effects of CERDELGA? See "What is the most important information I should know about CERDELGA?" CERDELGA used with certain other drugs may cause changes in the electrical activity of the heart (ECG changes) and irregular heartbeats (arrhythmia). Tell the doctor if you have new symptoms, such as heart pits, fainting, or dizziness. The most common side effects of CERDELGA include: fatigue, headache, nausea, diarrhea and pain in the arms, legs, back or stomach (abdomen). Tell your doctor if you have any side effects that bother you or that will not go away. These are not all possible side effects of CERDELGA. Call your doctor...

  CYSTAGON (Cysteamine tartrate) capsules 50 mg and 150 mg description CYSTAGON® (cysteamine tartrate) capsules contain cysteamine tartrate, which is a cystine depleting agent that reduces the content of cystine in the cells of patients with cystinopathy, which is an inheritance of lysosomal transport defect. CYSTAGON® (cysteamine tartrate) is the hydrogen tartrate salt of cysteamine (an amino mercaptan, β-mercaptoethylamine). Cysteine ​​bitartrate is a highly water-soluble white powder with a molecular weight of 227 and a molecular formula of C2H7NS•C4H6O6. Has the following chemical structure: CYSTAGON® (cysteamine tartrate) structure diagram Each CYSTAGON® (cysteamine tartrate) capsule contains 50 mg or 150 mg of cysteamine free base, such as cysteamine tartrate. CYSTAGON® (cysteamine tartrate) capsules contain the following inactive ingredients: colloidal silica, croscarmellose sodium, D&C yellow. 10 aluminum color lake water, FD&C blue. 1 aluminum lake, FD&C blue. ...

  What is Jardiance? how to use? Jardiance (empagliflozin) is an inhibitor of sodium-glucose cotransporter 2 (SGLT2) and can be used as an aid to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Jardiance can also reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease. What are the side effects of cleverness? Common side effects of Jardiance include: Dehydration dizziness, Dizziness, weakness, Yeast infections, Hypoglycemia, nausea, Upper respiratory tract infection, High cholesterol, Joint pain, Increased urination, Urinary Tract Infection Thirsty, and Low blood pressure (hypotension). description JARDIANCE tablets contain imaggliflozin, which is an orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2). The chemical name of empagliflozin is D-glucitol, 1,5-anhydro-1-C- [4-chloro-3-[[4-[[((3S)-tetrahydro-3furanyl]oxy) ]Phenyl]methyl]phenyl]-, (1S). Its molecular formula is C23H27ClO7 and its mole...

 USES The drug is a combination of 2 drugs: Ertugliflozin and Sitagliptin. It can be used in conjunction with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs and sexual function problems. Proper control of diabetes can also reduce the risk of heart attack or stroke. The role of Ertugliflozin is to increase the removal of sugar by the kidneys. Sitagliptin works by increasing a natural substance called incretin. Enterostatin helps control blood sugar by increasing the release of insulin, especially after meals. They also reduce the sugar produced by the liver. How to use Ertugliflozin 5 Mg-Sitagliptin 100 Mg tablets Please read the Medication Guide provided by your pharmacist before starting to take Erpagliflozin/Sitagliptin and each time you supplement it. If you have any questions, please consult your doctor or pharmacist. Follow your d...